
    
      This clinical trial is a designed as a prospective, multi-site, non-randomized study of 20
      subjects. Subjects will receive up to 5 study treatments completed 21 days apart. Phone
      follow-up will occur at Day 3 following each treatment for the assessment of adverse events
      and expected treatment effects. Post-treatment follow-up will be completed prior to the next
      subsequent treatment and at Days 30, 90 and 180 following the last treatment to assess
      adverse events and expected treatment effects, capture digital images, and assess efficacy.
    
  